RxDoctor Payments Data

Inessa Essaian, MD

Psychiatry · Glendale, CANPI 1366402976

Payments from drug & device makers

$1,125in general payments, 2019–2025

Across 53 payments — averaging $21.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$255
  • Johnson & Johnson$228
  • Vanda Pharmaceuticals Inc.$121
  • Otsuka America Pharmaceutical, Inc.$114
  • Lundbeck LLC$106
  • Takeda Pharmaceuticals U.S.A., Inc.$93
  • plus $208 from 6 others

What the payments were for

  • Food & beverage$1,125100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,125 in reported general payments places this provider in the 75th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$14,844
Medicare patients
49
Services billed
124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate47$104,981
Lurasidone Hcl74$24,979
Aripiprazole121$4,668
Olanzapine70$1,641
Bupropion XlBupropion Hcl118$1,635
Quetiapine Fumarate137$1,629
Divalproex Sodium ErDivalproex Sodium81$1,251
Trazodone Hcl191$1,238
Buspirone Hcl96$1,077
Oxcarbazepine16$1,062
Clozapine12$668
Prazosin Hcl45$659
Divalproex Sodium41$639
Escitalopram Oxalate209$622
Duloxetine Hcl28$618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$228$104,98147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →